Prevalence of intratumoral regulatory T cells expressing neuropilin-1 is associated with poorer outcomes in patients with cancer.

ABSTRACT: Despite the success of immune checkpoint blockade therapy, few strategies sufficiently overcome immunosuppression within the tumor microenvironment (TME). Targeting regulatory T cells (T_regs) is challenging, because perturbing intratumoral T_reg function must be specific enough to avoid systemic inflammatory side effects. Thus, no T_reg-targeted agents have proven both safe and efficacious in patients with cancer. Neuropilin-1 (NRP1) is recognized for its role in supporting intratumoral T_reg function while being dispensable for peripheral homeostasis. Nonetheless, little is known about the biology of human NRP1⁺ T_regs and the signals that regulate NRP1 expression. Here, we report that NRP1 is preferentially expressed on intratumoral T_regs across six distinct cancer types compared to healthy donor peripheral blood [peripheral blood lymphocyte (PBL)] and site-matched, noncancer tissue. Furthermore, NRP1⁺ T_reg prevalence is associated with reduced progression-free survival in head and neck cancer. Human NRP1⁺ T_regs have broad activation programs and elevated suppressive function. Unlike mouse T_regs, we demonstrate that NRP1 identifies a transient activation state of human T_regs driven by continuous T cell receptor (TCR) signaling through the mitogen-activated protein kinase pathway and interleukin-2 exposure. The prevalence of NRP1⁺ T_regs in patient PBL correlates with the intratumoral abundance of NRP1⁺ T_regs and may indicate higher disease burden. These findings support further clinical evaluation of NRP1 as a suitable therapeutic target to enhance antitumor immunity by inhibiting T_reg function in the TME.

SUBMITTER: Chuckran CA 

PROVIDER: S-EPMC9022491 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature